Advertisement
ABBV or JNJ or REGN
Which Stock Would AI Choose? AbbVie (ABBV) vs. Johnson & Johnson (JNJ) vs. Regeneron (REGN) Stock Comparison
Key Takeaways
- ABBV shares have gained around 9.7% in recent weeks, driven by positive Phase 3 data for SKYRIZI and strong immunology portfolio growth, with a 3.04% dividend yield.
- JNJ leads year-to-date with 18% gains, supported by Q4 earnings beats, FDA approvals like TECVAYLI plus DARZALEX, and robust 2026 guidance exceeding estimates.
- REGN shows stability with modest recent gains around 0.3%, bolstered by Dupixent expansions and oncology pipeline progress, though YTD slightly down amid Eylea competition.
- JNJ offers the strongest momentum and diversification across pharma and medtech, while ABBV provides higher yield and immunology focus; REGN appeals for biotech growth potential.
- All three exhibit solid market caps over $80B, with analyst upside: ABBV +9.2%, JNJ -4.1% (near targets), REGN strong buy consensus.
Introduction
This comparison examines ABBV, JNJ, and REGN, three leading healthcare stocks with significant exposure to immunology, oncology, and biopharma innovation. These companies navigate patent dynamics, pipeline advancements, and sector rotations amid evolving market conditions. Investors seeking relative performance insights, dividend stability, or growth catalysts in pharmaceuticals will find value here, as recent earnings, trial data, and guidance highlight contrasts in momentum, valuation, and risk profiles for informed stock comparison decisions.
ABBV Overview and Recent Performance
AbbVie (ABBV), a research-driven biopharmaceutical firm based in North Chicago, specializes in immunology, oncology, neuroscience, and aesthetics, with blockbusters like Skyrizi, Rinvoq, Imbruvica, and Botox anchoring its portfolio. In recent market activity, ABBV shares have advanced approximately 9.7% over the past month, trading near $228, supported by positive topline Phase 3 AFFIRM results for SKYRIZI in Crohn's disease and Phase 1 data for ABBV-295 in obesity. Q4 2025 adjusted EPS beat estimates at $2.71, with 2026 guidance for $14.37-$14.57 EPS and $67B revenues, offsetting Humira erosion via immunology growth exceeding 40% YoY. A 3.04% dividend yield enhances appeal, though oncology competition tempers sentiment.
JNJ Overview and Recent Performance
Johnson & Johnson (JNJ), a diversified healthcare giant headquartered in New Brunswick, New Jersey, operates in innovative medicine and MedTech, spanning oncology, immunology, neuroscience, cardiovascular, orthopedics, and vision care. Recent trading reflects strength, with shares up 18% YTD near $243, fueled by Q4 2025 sales of $24.6B (9.1% growth) and EPS of $2.46 beating estimates, alongside 2026 guidance for $99.5B-$100.5B sales and $11.43-$11.63 EPS above consensus. FDA approvals like TECVAYLI plus DARZALEX for multiple myeloma and positive pipeline updates have lifted sentiment, complemented by a 2.14% yield. Diversification mitigates pharma risks, supporting outperformance versus peers.
REGN Overview and Recent Performance
Regeneron Pharmaceuticals (REGN), a fully integrated biotech in Tarrytown, New York, focuses on eye diseases, inflammation, cancer, and rare diseases via Eylea, Dupixent, Libtayo, and linvoseltamab. Shares have traded stably around $775, with modest 0.3% recent gains but YTD flatness amid Eylea declines offset by Dupixent's 32% growth to $4.9B in Q4. Q4 revenue hit $3.88B beating estimates, with oncology and pipeline expansions like olatorepatide Phase 3 obesity data bolstering outlook. Attractive multiples and Strong Buy ratings signal biotech stability, though limited near-term catalysts may cap momentum versus diversified peers.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots, curated from hundreds available that trade thousands of tickers across diverse strategies, timeframes, and market conditions. These bots leverage AI/ML for technical and fundamental analyses, with trending selections highlighting those excelling in volatility—such as up to +217% annualized returns, 70-95% win rates, and profit factors to 12.5 on tickers in semiconductors, energy, aerospace, and biotech. Examples include a 15min multi-sector bot at +132% annualized (62% win rate, 25 tickers) and volatility plays like USAR/SMR at +217% (77% win rate). Varying styles from trend-following to hedging ensure adaptability. Explore Trending AI Robots to identify bots suited to current dynamics.
Head-to-Head Comparison
ABBV, JNJ, and REGN contrast in business models: ABBV and REGN emphasize biopharma R&D in immunology/oninology, while JNJ balances pharma with MedTech for stability. Growth drivers differ—ABBV's Skyrizi/Rinvoq (40%+ YoY), JNJ's Darzalex/TECVAYLI approvals, REGN's Dupixent expansions—amid Humira/Eylea erosions. Recent momentum favors JNJ (18% YTD) over ABBV (0.45%) and REGN (flat). Risks include competition (e.g., Bimzelx vs. Skyrizi) and pipeline delays; all share healthcare exposure but JNJ diversifies. Valuations: REGN cheapest P/E ~19x, ABBV 96x on growth, JNJ 22x balanced. Sentiment tilts positive on catalysts, with JNJ most resilient.
Tickeron AI Verdict
Tickeron’s AI currently favors JNJ for its trend consistency, YTD outperformance, diversified exposure, and upward guidance revisions, positioning it strongly amid healthcare rotations. ABBV trails slightly on valuation but shows immunology momentum; REGN offers upside via pipeline but lags stability. Probabilistic edge to JNJ based on relative strength.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 2 FA rating(s) are green whileJNJ’s FA Score has 3 green FA rating(s), and REGN’s FA Score reflects 2 green FA rating(s).
- ABBV’s FA Score: 2 green, 3 red.
- JNJ’s FA Score: 3 green, 2 red.
- REGN’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 6 TA indicator(s) are bullish while JNJ’s TA Score has 3 bullish TA indicator(s), and REGN’s TA Score reflects 2 bullish TA indicator(s).
- ABBV’s TA Score: 6 bullish, 4 bearish.
- JNJ’s TA Score: 3 bullish, 6 bearish.
- REGN’s TA Score: 2 bullish, 7 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а +1.04% price change this week, while JNJ (@Pharmaceuticals: Major) price change was -1.79% , and REGN (@Biotechnology) price fluctuated +0.23% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.21%. For the same industry, the average monthly price growth was +2.48%, and the average quarterly price growth was +7.89%.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.61%. For the same industry, the average monthly price growth was +9.02%, and the average quarterly price growth was +11.47%.
Reported Earning Dates
ABBV is expected to report earnings on Apr 29, 2026.
JNJ is expected to report earnings on Jul 22, 2026.
REGN is expected to report earnings on Apr 29, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.21% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Biotechnology (+7.61% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| ABBV | JNJ | REGN | |
| Capitalization | 369B | 564B | 79.4B |
| EBITDA | 17.6B | 41.1B | 5.82B |
| Gain YTD | -7.305 | 13.759 | -2.643 |
| P/E Ratio | 87.92 | 21.23 | 18.09 |
| Revenue | 61.2B | 94.2B | 14.3B |
| Total Cash | N/A | 20.1B | 8.61B |
| Total Debt | 67.5B | 47.9B | 2.71B |
ABBV | JNJ | REGN | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 60 | 59 | 63 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 35 Fair valued | 26 Undervalued | 3 Undervalued | |
PROFIT vs RISK RATING 1..100 | 14 | 11 | 75 | |
SMR RATING 1..100 | 1 | 27 | 54 | |
PRICE GROWTH RATING 1..100 | 55 | 46 | 26 | |
P/E GROWTH RATING 1..100 | 40 | 41 | 40 | |
SEASONALITY SCORE 1..100 | n/a | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
REGN's Valuation (3) in the Biotechnology industry is in the same range as JNJ (26) in the Pharmaceuticals Major industry, and is in the same range as ABBV (35) in the Pharmaceuticals Major industry. This means that REGN's stock grew similarly to JNJ’s and similarly to ABBV’s over the last 12 months.
JNJ's Profit vs Risk Rating (11) in the Pharmaceuticals Major industry is in the same range as ABBV (14) in the Pharmaceuticals Major industry, and is somewhat better than the same rating for REGN (75) in the Biotechnology industry. This means that JNJ's stock grew similarly to ABBV’s and somewhat faster than REGN’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is in the same range as JNJ (27) in the Pharmaceuticals Major industry, and is somewhat better than the same rating for REGN (54) in the Biotechnology industry. This means that ABBV's stock grew similarly to JNJ’s and somewhat faster than REGN’s over the last 12 months.
REGN's Price Growth Rating (26) in the Biotechnology industry is in the same range as JNJ (46) in the Pharmaceuticals Major industry, and is in the same range as ABBV (55) in the Pharmaceuticals Major industry. This means that REGN's stock grew similarly to JNJ’s and similarly to ABBV’s over the last 12 months.
REGN's P/E Growth Rating (40) in the Biotechnology industry is in the same range as ABBV (40) in the Pharmaceuticals Major industry, and is in the same range as JNJ (41) in the Pharmaceuticals Major industry. This means that REGN's stock grew similarly to ABBV’s and similarly to JNJ’s over the last 12 months.
| ABBV | JNJ | REGN | |
|---|---|---|---|
| RSI ODDS (%) | 3 days ago 63% | N/A | N/A |
| Stochastic ODDS (%) | 3 days ago 58% | 3 days ago 42% | 3 days ago 75% |
| Momentum ODDS (%) | 3 days ago 65% | 3 days ago 52% | 3 days ago 52% |
| MACD ODDS (%) | 3 days ago 67% | 3 days ago 32% | 3 days ago 49% |
| TrendWeek ODDS (%) | 3 days ago 58% | 3 days ago 40% | 3 days ago 66% |
| TrendMonth ODDS (%) | 3 days ago 51% | 3 days ago 42% | 3 days ago 60% |
| Advances ODDS (%) | 11 days ago 57% | 11 days ago 44% | 19 days ago 64% |
| Declines ODDS (%) | 7 days ago 48% | 3 days ago 41% | 4 days ago 51% |
| BollingerBands ODDS (%) | 3 days ago 62% | 3 days ago 48% | 3 days ago 49% |
| Aroon ODDS (%) | 3 days ago 43% | 3 days ago 38% | 3 days ago 70% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| NETG | 10.89 | 0.34 | +3.26% |
| Leverage Shares 2X Long NET Daily ETF | |||
| HELX | 34.83 | 0.81 | +2.38% |
| Franklin Genomic Advancements ETF | |||
| FYT | 66.55 | 1.46 | +2.24% |
| First Trust Small Cap Val AlphaDEX® ETF | |||
| IJR | 135.39 | 2.70 | +2.03% |
| iShares Core S&P Small-Cap ETF | |||
| ULTY | 32.21 | 0.50 | +1.58% |
| YieldMax Ultra Option Income Strat ETF | |||
ABBV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with PFE. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then PFE could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | -0.29% | ||
| PFE - ABBV | 57% Loosely correlated | +1.25% | ||
| BMY - ABBV | 55% Loosely correlated | +2.05% | ||
| BIIB - ABBV | 51% Loosely correlated | +0.76% | ||
| AMGN - ABBV | 51% Loosely correlated | +1.69% | ||
| NVS - ABBV | 49% Loosely correlated | +1.50% | ||
More | ||||